Robeco Institutional Asset Management B.V. Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Robeco Institutional Asset Management B.V. grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 35.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 99,994 shares of the biopharmaceutical company’s stock after buying an additional 26,426 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Alnylam Pharmaceuticals were worth $23,530,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $33,000. Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $42,000. Finally, True Wealth Design LLC lifted its holdings in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.2 %

Shares of ALNY opened at $277.16 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company’s fifty day moving average is $250.02 and its two-hundred day moving average is $260.77. The firm has a market cap of $35.75 billion, a PE ratio of -105.79 and a beta of 0.34. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 EPS. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ALNY shares. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Barclays boosted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Scotiabank upped their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.